AU6462899A - Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes - Google Patents

Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes

Info

Publication number
AU6462899A
AU6462899A AU64628/99A AU6462899A AU6462899A AU 6462899 A AU6462899 A AU 6462899A AU 64628/99 A AU64628/99 A AU 64628/99A AU 6462899 A AU6462899 A AU 6462899A AU 6462899 A AU6462899 A AU 6462899A
Authority
AU
Australia
Prior art keywords
ischaemic
prophylaxis
therapy
active substances
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64628/99A
Inventor
Stephan Nees
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vascular Biotech GmbH
Original Assignee
Vascular Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19844116A external-priority patent/DE19844116A1/en
Application filed by Vascular Biotech GmbH filed Critical Vascular Biotech GmbH
Publication of AU6462899A publication Critical patent/AU6462899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mixtures of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes, containing at least one substance that inhibits contractility in venular endothelial cells e.g. a benzopyrone compound, excluding anticoagulant benzopyrone compounds such as dicumarol, and at least one cyclogenase 1 inhibitor, preferably at least one non-steroid antiphlogistic agent.
AU64628/99A 1998-08-06 1999-08-06 Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes Abandoned AU6462899A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19835674 1998-08-06
DE19835674 1998-08-06
DE19844116A DE19844116A1 (en) 1998-08-06 1998-09-25 Active ingredient combination especially for the prophylaxis and therapy of ischemic organ damage and reperfusion syndromes
DE19844116 1998-09-25
PCT/DE1999/002478 WO2000007578A2 (en) 1998-08-06 1999-08-06 Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes

Publications (1)

Publication Number Publication Date
AU6462899A true AU6462899A (en) 2000-02-28

Family

ID=26047989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64628/99A Abandoned AU6462899A (en) 1998-08-06 1999-08-06 Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes

Country Status (4)

Country Link
EP (1) EP1100539B1 (en)
AT (1) ATE228011T1 (en)
AU (1) AU6462899A (en)
WO (1) WO2000007578A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021507A2 (en) * 1998-10-12 2000-04-20 Andreas Bockelmann Pharmaceutically active composition
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate

Also Published As

Publication number Publication date
EP1100539B1 (en) 2002-11-20
WO2000007578A3 (en) 2000-05-11
ATE228011T1 (en) 2002-12-15
EP1100539A2 (en) 2001-05-23
WO2000007578A2 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
PT949899E (en) DENTIFICAL COMPOSITIONS CONTAINING POLYPHOSPHATE AND FLUORIDE
TR200103810T2 (en) Fungicidal active compound combinations.
AU6805701A (en) Preservation and storage medium for biological materials
BG106242A (en) Metalloprotease inhibitors
ES2167546T3 (en) IMPROVEMENTS INTRODUCED IN ORGANIC COMPOSITIONS.
CA2416169A1 (en) Compositions containing therapeutically active components having enhanced solubility
NZ508884A (en) synergistic mixture of fungicidal compounds
IS3313A7 (en) Method of transporting products packed in units, which emit moisture and require cooling, as well as packaging for use in carrying out the method.
ES2060825T3 (en) A THERAPEUTIC SYSTEM FOR DELAYED AND CONTROLLED ADMINISTRATION OF ACTIVE SUBSTANCES BY VIA PERCUTANEA OR THROUGH THE MUCOSA.
MXPA02012160A (en) Medicinal compositions containing propenone derivatives.
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
HU9203286D0 (en) Inflammation inhibiting hydrosame acids and n-hydroxi-ureas
EP1249240A4 (en) Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
AU6462899A (en) Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes
ES2124983T5 (en) USE OF AN SUBSTANCE ANTAGONIST P FOR THE TREATMENT OF RED CUTANEOUS STAINS OF NEUROGEN ORIGIN.
SE8403912D0 (en) PHARMACEUTICAL KIT OR COMPOSITION
AU2164999A (en) Wood preservation agents
DE59409275D1 (en) Tablets with certain grain size thioctic acid
NO20015108D0 (en) Complete feed for fish larvae and process for producing the same
AR047074A1 (en) PROCESS FOR DISINFECTION AND / OR CONSERVATION OF HARVESTED VEGETABLE MATTERS
ES2046422T3 (en) ANTIMICROBIAL COMPOSITION AND METHOD OF USE.
MY107976A (en) Improvements in or relating to organic compounds
BR0012792A (en) Antibacterial compositions of hops acid, and method for reducing the number of gram-positive bacteria in food and non-food products
EP0948961A3 (en) Effervescent tablet comprising Calcium with an antihistaminic as active agent
AU8452891A (en) Calcium uptake inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase